Status:
COMPLETED
Nigella Sativa Supplementation in Hyperlipidemia Treatment
Lead Sponsor:
Istanbul Bilgi University
Conditions:
Hyperlipidaemia
Hyperlipidemia
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Hyperlipidemia is defined as an elevation of plasma cholesterol, lipid, or lipoprotein levels above normal due to abnormal fat metabolism or function, and individuals with hyperlipidemia are approxima...
Detailed Description
This research, which is a randomized controlled intervention study, was conducted between June 2023 and February 2024 with adult individuals with a BMI\>25 kg/m2 who applied to the Cardiology Polyclin...
Eligibility Criteria
Inclusion
- Adults individuals who were diagnosed hyperlipidemia
- Individuals suitable for taking Nigella satvia supplement
- Individuals BMI\>25 kg/m2
Exclusion
- Chronic liver disease,
- Chronic kidney disease,
- Heart failure, infarction or cerebrovascular disease,
- Pregnant and breastfeeding women,
- Severe psychiatric disorders,
- Oncological diseases,
- Individuals using medications that could interact with black seed oil (anticoagulant, antihypertensive, etc.)
- Individuals using antilipidemic or anticholesterolemic medications
- Individuals did not do heavy exercise
- Individuals using any nutritional supplement
- Individuals have a known history of allergy
- Individuals did not consume alcohol regularly
- Individuals with special dietary needs
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT06890546
Start Date
June 1 2023
End Date
February 28 2025
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
İstanbul Bilgi University
Istanbul, Turkey (Türkiye)